We are live on ! Find out more
BDRX

Biodexa Pharmaceuticals
BDRX

7 hedge funds and large institutions have $228K invested in Biodexa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

6.95% less ownership

Funds ownership: 9.86% → 2.9% (-7%)

13% less funds holding

Funds holding: 8 → 7 (-1)

67% less capital invested

Capital invested by funds: $693K → $228K (-$465K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
–
Increased
3
Reduced
3
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SM
Sabby Management
Florida
+$94K
2
GI
GAMMA Investing
California
+$16.9K
3
SS
SBI Securities
Japan
+$70

Top Sellers

1
HF
HRT Financial
New York
-$24K
2
AC
Armistice Capital
New York
-$3.49K
3
UBS Group
UBS Group
Switzerland
-$2.78K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$7
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$159K +$94K +13,362 +35%
AC
2
Armistice Capital
New York
$60.3K -$3.49K -496 -2%
GI
3
GAMMA Investing
California
$8.52K +$16.9K +2,401 +676%
SS
4
SBI Securities
Japan
$93 +$70 +10 +50%
UBS Group
5
UBS Group
Switzerland
$78 -$2.78K -395 -94%
HHCP
6
Hilton Head Capital Partners
South Carolina
$19 – – –
RhumbLine Advisers
7
RhumbLine Advisers
Massachusetts
$11 -$7 -1 -20%
CIAM
8
Caitong International Asset Management
Hong Kong
$1 – – –
HF
9
HRT Financial
New York
– -$24K -2,117 Closed